Wissam Baghdadi

Engineer Process Development • Sangamo Therapeutics

Wissam Baghdadi is Sangamo’s Engineer in Process Development, and in this role he develops manufacturing processes for Sangamo’s cell therapies using gene edited regulatory T cells, or Tregs. He is notably in charge of optimizing cell purity, quality, and quantity. Wissam notably played a key role in developing Sangamo’s proprietary CAR-Treg manufacturing process used in the first-in-human STEADFAST clinical study. He is also closely involved in the transfer of Sangamo’s processes to manufacturing teams, both internally and externally.

Wissam has been with Sangamo Therapeutics France – formerly known as TxCell prior to its acquisition by Sangamo in 2018 – since 2014.

Also Speaking

Steven B. Miller

Farzin Farzaneh

Chief Scientific Officer • ViroCell Biologics

Samik Upadhaya

Assistant Director of Scientific Affairs • Cancer Research Institute

Also Speaking


Investor List

Take a look at some of the investors who attended Advanced Therapies Week 2023.


Find out more and apply to get involved at the briefings taking place at Advanced Therapies Week.